The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.

[1]  D. Kwong,et al.  Preliminary results of trial NPC‐0501 evaluating the therapeutic gain by changing from concurrent‐adjuvant to induction‐concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally a , 2015, Cancer.

[2]  Jiang Li,et al.  Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma , 2015, Oncoimmunology.

[3]  P. Boscolo-Rizzo,et al.  Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice , 2015, European Archives of Oto-Rhino-Laryngology.

[4]  S. Leung,et al.  Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Chong Zhao,et al.  Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Ying Huang,et al.  Comparing treatment outcomes of different chemotherapy sequences during intensity modulated radiotherapy for advanced N-stage nasopharyngeal carcinoma patients , 2013, Radiation oncology.

[7]  Y. Mao,et al.  Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. King,et al.  Early detection of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA analysis in a surveillance program , 2013, Cancer.

[9]  Y. Shih,et al.  Long‐term survival analysis of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA levels , 2013, Cancer.

[10]  A. Garden,et al.  Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. , 2012, The Lancet. Oncology.

[11]  T. Ciuleanu,et al.  Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  R. Miceli,et al.  Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Chong Zhao,et al.  Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  C. Qian,et al.  The prevalence and prevention of nasopharyngeal carcinoma in China , 2011, Chinese journal of cancer.

[15]  P. Gabriele,et al.  Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma , 2011, Cancer Chemotherapy and Pharmacology.

[16]  Jin-Ching Lin,et al.  Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma , 2010, Clinical Cancer Research.

[17]  Jianji Pan,et al.  Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: Experience of 370 consecutive cases , 2010, BMC Cancer.

[18]  A. King,et al.  Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Mengzhong Liu,et al.  [Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma]. , 2009, Ai zheng = Aizheng = Chinese journal of cancer.

[20]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[21]  Anne W. M. Lee,et al.  Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  N. Toumi,et al.  Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma. , 2007, Cancer treatment reviews.

[23]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[24]  H. Heslop,et al.  Adoptive Immunotherapy for EBV-associated Malignancies , 2005, Leukemia & lymphoma.

[25]  Jun Ma,et al.  Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Yau-Huei Wei,et al.  Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.

[27]  Chen-Yi Hsu,et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Leung,et al.  Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. , 2002, Journal of the National Cancer Institute.

[29]  P. Lou,et al.  Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Hesseling,et al.  PROGNOSTIC VALUE OF DAY 14 BLAST PERCENTAGE AND THE ABSOLUTE BLAST INDEX IN BONE MARROW OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA , 2001, Pediatric hematology and oncology.

[31]  S. Leung,et al.  Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.

[32]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Ferrari,et al.  Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Rosen,et al.  Primary osteogenic sarcoma of the femur: a model for the use of preoperative chemotherapy in high risk malignant tumors. , 1984, Cancer investigation.

[35]  G. Choa.  Nasopharyngeal carcinoma. Some observations on the clinical features and technique of examination. , 1967, Pacific medicine and surgery.